This report from Life Science Intelligence provides the latest market data for the Global Renal Denervation Catheters Market. Information covered by this report includes:
· unit volumes & pricing forecast from 2019-2024
· analyses of the leading companies, and
· global market share analysis.
The global market for renal denervation catheters was valued at an estimated $45.8 million in 2020 and is projected to decrease at a CAGR (2020-2024) of (-1.8%). Products covered by this report include renal denervation catheters for the treatment of hypertension.
This report covers the impact of COVID-19 on the renal denervation catheters market, including a recent forecast from 2020 to 2024. COVID-19 has also impacted leading competitors, such as Boston Scientific, Medtronic, Otsuka, and others. The report provides insights into trends, drivers, and limiters of the renal denervation catheters market, as well as highlights potential opportunities.
The renal denervation catheters market has been severely inhibited by the COVID-19 pandemic. The pandemic has affected elective surgical procedures markedly, as many non-critical procedures have been cancelled or postponed so that healthcare resources have been conserved for the treatment of COVID-19 and other critically ill patients. The market is expected to remain flat or slowly decline at a low single-digit rate until the publication of strong clinical evidence to support the efficacy of renal denervation.
Medtronic is the market leader with an estimated market share of approximately 80% of the global renal denervation catheters market. Boston Scientific (Vessix), ReCor Medical (Paradise), ROX Medical (ROX Coupler), and Vascular Dynamics (MobiusHD) are other competitors in the renal denervation catheters market.